



# *Cardiac arrhythmias in critically ill patients*

**Essay**

**Submitted for partial fulfillment for master degree  
in Intensive care medicine**

**By**

**Mahmoud El-shahat Awad Makhluaf  
M.B.B.Ch.**

***Supervisors***

**Prof. Dr. Ibrahim Abd El-Ghany Ibrahim**

Professor of anesthesia and ICU  
Faculty of Medicine - Ain Shams University

**Dr. Ahmed Mohamed Shafik**

Assistant Professor of Anesthesia and ICU  
Faculty of Medicine - Ain Shams University

**Dr. Mayar Hassan El-Sersi**

Lecturer of Anesthesia and ICU  
Faculty of Medicine - Ain Shams University

Faculty of Medicine  
Ain Shams University  
2010

---

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# ***Cardiac arrhythmias in critically ill patients***

**A Protocol of An Essay**

**Submitted for partial fulfillment for master degree  
in Intensive care medicine**

By

**Mahmoud El-shahat Awad Makhluf**  
M.B.B.Ch.

*Supervisors*

**Prof. Dr. Ibrahim Abd El-Ghany Ibrahim**

Professor of anesthesia and ICU  
Faculty of Medicine- Ain Shams University

**Dr. Ahmed Mohamed Shafik**

Assistant Professor of Anesthesia and ICU  
Faculty of Medicine- Ain Shams University

**Dr. Mayar Hassan El-Sersi**

Lecturer of Anesthesia and ICU  
Faculty of Medicine- Ain Shams University

Faculty of Medicine  
Ain Shams University  
2009

---

## ***Introduction***

Although most hearts beat with remarkable fidelity and resilience, under certain circumstances the rhythm of the heart can fail. This is known as a cardiac arrhythmia. Cardiac arrhythmias are a leading cause of morbidity and mortality(***Keating MT and Sanguinetti MC,2001***).

Critically ill patients often have underlying heart disease, are frequently submitted to metabolic, ischemic, or neurohormonal stressors, and are therefore particularly at risk for cardiac arrhythmias(***Trohman RG and Parrillo JE,2000***).

Arrhythmias are common in the intensive care unit and represent a major source of morbidity and increased length of stay (***Hollenberg SM,2007***). The recent reported incidence of cardiac arrhythmias in a large, prospective, multicenter study in a general ICU populations is about 12%. Atrial fibrillation was the most common form of arrhythmia(***Annane D et al.,2008***). An arrhythmia incidence of up to 78% has been reported in a single center retrospective study with atrial fibrillation being the prominent clinical problem. Arrhythmias were more likely to occur in patients admitted in the ICU for cardiovascular disorders and were associated with an increased risk of death(***Artucio H and Pereira M,1990***). However, this retrospective study was too inclusive, including even patients with ventricular or supraventricular premature beats or bundle branch block which do not represent the common perception of a significant sustained arrhythmia. Arrhythmias are most likely to occur in patients with structural heart disease. The inciting factor for an arrhythmia in a given patient may be a transient imbalance, often related to hypoxia, infection, cardiac ischemia, catecholamine excess (endogenous or exogenous), or an electrolyte abnormality (***Hollenberg SM,2007***).

Normal heart rhythm requires the finely orchestrated activity of a number of ion channels and transporters and the orderly propagation of electrical impulses throughout the myocardium; disruption of either can have severe consequences, resulting in potentially lethal heart rhythm disturbances. The generation of

---

cardiac arrhythmias requires the presence of a susceptible myocardial substrate and an appropriate trigger. Although any heart may serve as a substrate for the development of a potentially serious cardiac arrhythmia, in structurally normal hearts this is rare and requires highly potent triggers. Understanding the basic biology of arrhythmogenesis holds the promise of identifying novel targets for the treatment of arrhythmias, including prevention of the development of structural changes in the heart that form the substrate for cardiac rhythm disturbances(*Shah M et al., 2005*). Cardiac arrhythmias are generally produced by one of three mechanisms: enhanced automaticity, triggered activity, or reentry(*Podrid PJ,2008*).

Patients with cardiac arrhythmias may come to the attention of their physicians in a variety of ways. An asymptomatic arrhythmia may be fortuitously discovered on a routine electrocardiogram or physical exam. Alternatively, a patient may present with a complaint suggestive of arrhythmia, usually palpitations, syncope, or presyncope. Finally, patients who have no history of arrhythmia, but who may be prone to ventricular tachyarrhythmias because of underlying heart disease, may undergo routine testing to evaluate their level of risk. Patients in each category may be evaluated by invasive or noninvasive means(*Richardson AW and Zimetbaum PJ,2002*).

In the management of clinical arrhythmias, the physician must evaluate and treat the whole patient, not just the rhythm disturbance. Evaluation of the patient begins with a careful history and physical examination and should usually progress from the simplest to the most complex test, from the least invasive and safest to the most invasive and risky, and from the least expensive out-of-hospital evaluations to those that require hospitalization and sophisticated, costly procedures(*Zipes DP and Miles WM,2004*). In the great majority of cases the correct diagnosis can be determined at the initial consultation after careful analysis of the history, findings at clinical examination, and 12-lead ECG(*Garratt C,2001*).

When present or expected, dysrhythmia should be managed seriously. Hemodynamic status may be compromised by bradycardia, tachycardia, loss of atrial transport function,or

---

ineffective ventricular contractions(*Thompson A and Balser JR,2004*). The physiologic impact of a dysrhythmia depends on ventricular response rate, duration of dysrhythmia, and underlying cardiac function( *Heintz KM and Hollenberg SM,2005*).

The presence of a dysrhythmia or cardiac conduction disturbance should provoke a careful evaluation for the underlying cardiopulmonary disease, drug toxicity, or metabolic abnormality. Therapy should be initiated for symptomatic or hemodynamically significant dysrhythmias, first to reverse an underlying cause and second to treat the dysrhythmia(*Fleisher LA et al., 2007*).

In the past, pharmacologic therapy was the cornerstone of treatment for symptomatic and life-threatening ventricular arrhythmias. However, alternative nonpharmacologic therapy has received increasing attention because of the high failure rate, common proarrhythmic actions, and frequent toxicity of the antiarrhythmic drugs. Included in this group are the implantable cardioverter-defibrillator (ICD), catheter ablation, and, at times, cardiac surgery. Electrophysiologic cardiac mapping techniques play an integral role during catheter ablation of ventricular arrhythmias. Mapping permits precise localization of the myocardial sites of origin of focal rhythm disturbances(*Ganz LI and Arnsdorf MF,2008*). Catheter ablation has revolutionized the management of patients with tachyarrhythmias(*Morady F,1999*). More recently, cryoablation and other energy sources have been used in some specific clinical settings(*Ganz LI,2007*). Antidysrhythmic pharmacology is focused primarily on the cardiac ion channels and adrenergic receptors as drug targets. The number of drug targets for antidysrhythmic therapy is expanding exponentially(*Priori SG et al.,1999*). Currently available antidysrhythmic drugs are limited by modest efficacy and significant toxicity(*Page RL,2007*). An ideal antidysrhythmic agent does not exist, and drug selection should be highly individualized(*Koufakia M et al., 2006*). Thus, cardiologic intervention for dysrhythmias has evolved from pharmacologic therapy to surgically based elimination of dysrhythmogenic foci and circuits to transvenous catheter-based ablation procedures. It has dramatically changed the management of dysrhythmias(*Satti SD and Epstein LM,2003*). Also, Invasive

---

cardiac electrophysiology has evolved rapidly from a research tool to an established clinical technique for the investigation and treatment of cardiac rhythm disorders(*Rahimtoola SH et al.,1987*). Pacemaker and defibrillator management is increasingly complex and is a subject of comprehensive reviews(*Spotnitz HM 2003*).

Arrhythmias in critically ill patients should be probably understood and managed by every intensivist in order to improve intensive care outcome. We will try to cover some aspects about this issue in our work.

## *Aim of the Work*

Our study aims at discussing the most important causes of arrhythmias in critically ill patients, explaining how to diagnose and monitor them and presenting the recent methods of management, depending on clear understanding of the basic physiology, pathophysiology and molecular biology of arrhythmia.

## *References*

- **Artucio H and Pereira M.** Cardiac arrhythmias in critically ill patients: epidemiologic study. *Crit Care Med* 1990;18:1383-1388.
  - **Annane D, Sebille V, Duboc D, Le Heuzey JY, Sadoul N, Bouvier E, and Bellissant E.** Incidence and prognosis of sustained arrhythmias in critically ill patients. *Am J Respir Crit Care Med* Vol 178.pp 20-25, 2008.
  - **Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, and Robb JF.** ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) *Circulation*. 2007;116;1971-96.
  - **Ganz LI.** Catheter ablation of cardiac arrhythmias: Overview and technical aspects.UptoDate 2007.
  - **Ganz LI and Arnsdorf MF.** Catheter ablation for ventricular arrhythmias. UptoDate 2008.
  - **Garratt C.** Clinical management of the patient presenting with palpitation. In: (ed). *Mechanisms and Management of Cardiac Arrhythmias*. BMJ Publishing Group,London,2001;115-20.
  - **Heintz KM and Hollenberg SM.** Perioperative cardiac issues: postoperative arrhythmias. *Surg Clin North Am*. 2005 Dec;85(6);1103-14.
  - **Hollenberg SM.** Intensive care unit arrhythmias. In: Vincent JL (eds). *Intensive Care Medicine Annual Update* . Springer Science + Business Media Inc. New York,2007;431-43.
  - **Keating MT and Sanguinetti MC.** Molecular and cellular mechanisms of cardiac arrhythmias. *Cell*. 2001;104(4);569-80.
  - **Koufakia M, Kiziridia C, Papazafirib P, Vassilopoulosb A, Varróc A, Nagyc Z, Farkasc A, and Makriyannis A.** Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. *Bioorganic & Medicinal Chemistry*. 2006;14(19);666-78.
  - **Morady F.** Radio-frequency ablation as treatment for cardiac arrhythmias. *N Engl J Med* 1999; 340:534.
-



- **Page RL.** Medical management of atrial fibrillation: Future directions. *Heart Rhythm.* 2007;4(3);91-4.
- **Podrid PJ.** Reentry and the development of cardiac arrhythmias. *UptoDate* 2008.
- **Priori SG, Barhanin J, and Hauer RN.** Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. *Circulation.* 1999;99;518- 28.
- **Rahimtoola SH, Zipes DP, Akhtar M, et al.** Consensus statement of the Conference on the State of the Art of Electrophysiologic Testing in the Diagnosis and Treatment of Patients with Cardiac Arrhythmias. *Circulation* 1987; 75:3-11.
- **Richardson AW and Zimetbaum PJ.** The diagnosis of cardiac arrhythmias. In: Ganz LI, Braunwald E (eds). *Management of cardiac arrhythmias.* Humana Press New Jersey,2002;9-28.
- **Satti SD and Epstein LM.** Cardiology Interventional Therapy for Atrial and Ventricular arrhythmias. In: Cohn LH, Edmunds LH (eds). *Cardiac Surgery in the Adult.* McGraw- Hill,New York,2003;1253-70.
- **Shah M, Akar FG, and Tomaselli GF.** Molecular Basis of Arrhythmias. *Circulation.* 2005;112;2517-29.
- **Spotnitz HM.** Pacemakers and Automatic Defibrillators. In: Cohn LH, Edmunds LH (eds). *Cardiac Surgery in the Adult.* McGraw-Hill,New York,2003;1293-326.
- **Thompson A and Balser JR.** Perioperative cardiac arrhythmias. *Br J Anaesth.* 2004;93;86-94.
- **Trohman RG and Parrilo JE.** Arrhythmias: perceptive for the critical care physician. *Crit Care Med* 2000;28:170-173.
- **Zipes DP and Miles WM.** Assessment of the patient with a cardiac arrhythmia. In: Zipes DP, Jalife J (eds). *Electrophysiology from Cell to bedside.* 4th edn. WB Saunders Philadelphia,2004;759-64.

## **ACKNOWLEDGMENT**

Thanks to Allah from start to end, that this work has been completed.

First foremost, I am extremely grateful to ***Prof. Dr. Ibrahim Abd El-Ghani Ibrahim***, prof. of Anaesthesia and Intensive Care, Faculty of Medicine, Ain Shams university, for his kind supervision, valuable guidance and continous encouragement and I wish him a good health.

Also, I wish to express my great pleasure and deep gratitude to ***Assist. Prof. Dr. Ahmed Mohamed Shafik***, Assist. Prof. of Anaesthesia and Intensive Care, Faculty of Medicine, Ain Shams university, for his support, great help, and continous and valuable directions.

I would also like to thank ***Dr. Mayar Hassan El-Sersi***, lecturer of anaesthesia and Intensive Care, for her very helpful suggestions and encouragement. She spent a lot of her time for completing this work .

I would like to express my special thanks to all members of Anesthesiology and Intensive Care department, faculty of medicine, Ain Shams university for their valuable support. I would like to thank my family for every thing.

***Mahmoud El-shahat Awad Makhluf***  
***2010***

---

## *Contents*

	P a g e
Introduction .....	1
I) Anatomy and physiology .....	3
II) Pathophysiology of arrhythmia .....	20
III) Diagnosis and monitoring of arrhythmias .....	34
IV) Specific types of arrhythmias .....	49
V) Management of arrhythmias in critically ill patients.....	109
VI) Summary .....	142
VII) References .....	145
VIII) Arabic Summary.....	

---

## *List of figures*

<b>Figure I- 1 :</b>	<b>Posterior schematic of the heart with internodal pathways</b>	<b>4</b>
<b>Figure I-2 :</b>	<b>Organization of the A-V node</b>	<b>4</b>
<b>Figure I-3 :</b>	<b>Action potentials of different parts of the heart</b>	<b>12</b>
<b>Figure I-4 :</b>	<b>The action potential in ventricular muscle</b>	<b>13</b>
<b>Figure I-5 :</b>	<b>Rhythmical discharge of a sinus nodal fiber</b>	<b>16</b>
<b>Figure I-6 :</b>	<b>Refractory periods</b>	<b>18</b>
<b>Figure II-1:</b>	<b>Automaticity atrial and ventricular myocardium</b>	<b>23</b>
<b>Figure II-2:</b>	<b>Types of after depolarization currents</b>	<b>25</b>
<b>Figure II-3:</b>	<b>Triggered activity—early afterdepolarization</b>	<b>26</b>
<b>Figure II-4:</b>	<b>Triggered activity—delayed afterdepolarization</b>	<b>27</b>
<b>Figure II-5:</b>	<b>Cellular mechanism of delayed after depolarization</b>	<b>28</b>
<b>Figure II-6:</b>	<b>Reentry arrhythmia</b>	<b>29</b>
<b>FigureIII- 1 :</b>	<b>Resting ECG that suggest arrhythmia potential</b>	<b>39</b>
<b>FigureIII- 2 :</b>	<b>Photograph of the implantable loop recorder</b>	<b>39</b>
<b>FigureIII- 3 :</b>	<b>Differential diagnosis for narrow QRS tachycardia</b>	<b>41</b>
<b>FigureIII-4 :</b>	<b>Responses of narrow complex tachycardias to adenosine</b>	<b>41</b>
<b>FigureIII- 5 :</b>	<b>Differential diagnosis for wide complex tachycardia</b>	<b>42</b>
<b>FigureIII- 6 :</b>	<b>AV dissociation during VT</b>	<b>44</b>
<b>Figure IV-1:</b>	<b>Example of a paroxysmal atrial tachycardia</b>	<b>52</b>
<b>Figure IV- 2:</b>	<b>Multi-focal atrial tachycardia</b>	<b>55</b>
<b>Figure IV-3:</b>	<b>Classification of atrial fibrillation</b>	<b>57</b>
<b>Figure IV-4:</b>	<b>Modulating factors in initiation of atrial fibrillation</b>	<b>58</b>
<b>Figure IV-5:</b>	<b>Atrial fibrillation</b>	<b>60</b>
<b>Figure IV-6:</b>	<b>Management of atrial flutter</b>	<b>72</b>
<b>Figure IV-7:</b>	<b>Typical counterclockwise atrial flutter</b>	<b>72</b>
<b>Figure IV-8:</b>	<b>Atrio-ventricular nodal reentrant tachycardia</b>	<b>74</b>
<b>Figure IV-9:</b>	<b>Electrical Conduction in the WPW Syndrome</b>	<b>78</b>
<b>Figure IV-10:</b>	<b>Preexcitation in the WPW Syndrome</b>	<b>78</b>
<b>Figure IV-11:</b>	<b>Conduction system and accessory connections bypassing that system</b>	<b>79</b>

---

<b>FigureIV-12:</b>	<b>AVRT using fast and slow pathways</b>	<b>79</b>
<b>FigureIV-13:</b>	<b>Two types of circus movement tachycardias</b>	<b>80</b>
<b>FigureIV-14:</b>	<b>Locations of accessory AV connections</b>	<b>81</b>
<b>FigureIV-15:</b>	<b>The most common types of tachycardia in the WPW syndrome</b>	<b>81</b>
<b>FigureIV-16:</b>	<b>Deterioration of AF into VF in accessory AV pathway</b>	<b>82</b>
<b>FigureIV-17:</b>	<b>Prolongation of the refractory period in the AV pathway and accessory pathway by drugs</b>	<b>83</b>
<b>FigureIV-18:</b>	<b>Runs of ventricular tachycardia of uniform contour</b>	<b>84</b>
<b>FigureIV-19:</b>	<b>Torsade de pointes</b>	<b>86</b>
<b>FigureIV-20:</b>	<b>Management of hemodynamically tolerated wide-QRS tachycardia</b>	<b>88</b>
<b>FigureIV-21:</b>	<b>Management of hemodynamically unstable VT or VF</b>	<b>89</b>
<b>FigureIV-22:</b>	<b>Accelerated idioventricular rhythm</b>	<b>90</b>
<b>FigureIV-23:</b>	<b>Ventricular flutter and ventricular fibrillation</b>	<b>95</b>
<b>FigureIV-24:</b>	<b>Advanced life support cardiac arrest algorithm</b>	<b>97</b>
<b>FigureIV-25:</b>	<b>Sinus bradycardia</b>	<b>99</b>
<b>FigureIV-26:</b>	<b>The "tachy-brady syndrome"</b>	<b>101</b>
<b>FigureIV-27:</b>	<b>First-degree AV block</b>	<b>102</b>
<b>FigureIV-28:</b>	<b>2<sup>nd</sup> degree AV block (Mobitz type I)</b>	<b>102</b>
<b>FigureIV-29:</b>	<b>2<sup>nd</sup> degree AV block (Mobitz type II)</b>	<b>103</b>
<b>FigureIV-30 :</b>	<b>Third-degree atrioventricular block</b>	<b>103</b>
<b>FigureIV-31 :</b>	<b>Nonparoxysmal junctional tachycardia</b>	<b>106</b>
<b>FigureIV-32 :</b>	<b>Junctional ectopic tachycardia</b>	<b>107</b>
<b>Figure V-1 :</b>	<b>Management of hemodynamically stable regular tachycardia</b>	<b>111</b>
<b>Figure V-2 :</b>	<b>Prolongation of the QT interval of hypocalcemia</b>	<b>121</b>
<b>Figure V-3 :</b>	<b>ECG appearances of electrolyte abnormalities</b>	<b>122</b>
<b>Figure V-4 :</b>	<b>Electrocardiograms of proarrhythmia</b>	<b>127</b>
<b>Figure V-5 :</b>	<b>Diagram of a Single-Chamber ICD system</b>	<b>137</b>

## ***List of Tables***

<b>Table I-1: Ions as Charge Carriers across Cell Membranes</b>	<b>6</b>
<b>Table I-2: Phases of action potential in purkinje fibres</b>	<b>13</b>
<b>Table I-3: Conduction Speeds in Cardiac Tissue</b>	<b>17</b>
<b>Table II-1 : Common causes of abnormal cardiac electrophysiology</b>	<b>20</b>
<b>Table II-2: Mechanisms of Arrhythmogenesis</b>	<b>22</b>
<b>Table II-3: Factors That Influence Early Afterdepolarization</b>	<b>25</b>
<b>Table II-4: Conditions Known to Promote Torsades de Pointes</b>	<b>26</b>
<b>Table II-5 : Medications Potentially Cause Torsades de Pointes</b>	<b>32</b>
<b>Table III-1 : Causes of palpitations</b>	<b>34</b>
<b>Table III-2 : Disorders that Place Patients at Risk for Ventricular Arrhythmias</b>	<b>36</b>
<b>Table III-3 : Findings on CSM in different supraventricular tachyarrhythmias</b>	<b>37</b>
<b>Table III-4 : Conditions associated with arrhythmias diagnosed by echocardiography</b>	<b>38</b>
<b>Table III-5: ECG Diagnosis of Wide QRS Tachycardia</b>	<b>43</b>
<b>Table IV-1: Etiologies and factors predisposing patients to AF</b>	<b>57</b>
<b>Table IV-2: List of commonly used agents for rate control</b>	<b>64</b>
<b>Table IV-3: Drugs effective for pharmacological cardioversion of AF</b>	<b>66</b>
<b>Table IV-4: Antithrombotic therapy for patients with AF</b>	<b>69</b>
<b>Table IV-5: Risk-based approach to antithrombotic therapy in AF</b>	<b>69</b>
<b>Table IV-6: Nomenclature of accessory connections</b>	<b>79</b>
<b>Table IV-7: Clinical Presentations of Ventricular Arrhythmias and SCD</b>	<b>84</b>
<b>Table IV-8: Factors Aggravating Ventricular Arrhythmias</b>	<b>91</b>
<b>Table IV-9: Aetiologies of ventricular fibrillation</b>	<b>93</b>
<b>Table IV-10: Causes of sinus node dysfunction</b>	<b>100</b>
<b>Table V-1 : Calcium and magnesium disorders</b>	<b>121</b>
<b>Table V-2 : Vaughan-Williams Classification of Antiarrhythmics</b>	<b>126</b>
<b>Table V-3 : Disease-specific relative drug contraindications</b>	<b>126</b>
<b>Table V-4 : Classification of Tachyarrhythmias Based on Predicted Responses to Cardioversion/Defibrillation</b>	<b>129</b>
<b>Table V-5 : Generic code for antibradycardic pacing</b>	<b>133</b>

---

<b>Table V-6 : Indications for temporary pacing</b>	134
<b>Table V-7 : Major indications for ICD</b>	136
<b>Table V-8 : Complications of ICD therapy</b>	137